Bringing viral-based therapies to market can be complex. Collaborating with a trusted partner is essential to overcoming the range of challenges associated with the journey to market. This webinar will delve into the benefits of a customer-focused approach. We will explore the intricate challenges that customers have presented to us and the collaborative strategies deployed to effectively resolve them.
The discussion will be centered on our comprehensive experiences in handling oncolytic viruses. Specifically, we will focus on the intricacies involved in the production of egg-based vaccines, followed by an illuminating presentation of data related to adeno-associated virus (AAV).
The webinar will end by highlighting the establishment of redundant pathways for the production of commercial material. This will be exemplified through the strategic positioning of facilities in both Europe and the US. We will emphasize the inherent redundancies and flexibility within infrastructure and the supply chain.
Webinar Learning Objectives:
- Drawing upon our extensive experience in viral-based therapeutics manufacturing, we will illustrate the benefits of partnering with right CDMO partner. The essential involvement of a CDMO will provide access to the intricate processes required to produce viral-based therapeutics.
- We will highlight the advantages and efficiencies gained from partnering with a CDMO which has the capacity to produce viral-based commercial processes in both Europe and the US. This will underline the substantial time and monetary savings afforded to clients through strategic transcontinental operations.
